Expertise in
3
conditions

Antoine Durrbach

Paris, FR 
Expertise in
3
conditions
Paris, FR 

Overview

Antoine Durrbach practices practicing medicine in Paris, France.

Mr. Durrbach is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Chronic Kidney Disease, Focal Segmental Glomerulosclerosis, Glomerulonephritis, Kidney Transplant, and Hepato-Pancreato-Biliary Surgery.

He is actively involved in clinical research, co-authoring 113 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Paris, France
Other Locations
Creteil, France
Villejuif, France
Orsay, France
Le Kremlin Bicêtre, France
Grenoble, France
CHU Strasbourg, Dialysis and Renal Transplantation
Strasbourg, France
Dialysis and Renal Transplantation
Besancon, 25000, France
Plateau, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial
Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 20, 2026
Intervention Type: Other, Drug
Study Phase: Phase 3
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Autosomal Dominant Polycystic Kidney Disease
Enrollment Status: Terminated
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drug: Bardoxolone
Study Phase: Phase 3
BKVIR Project: Predictive Biological Method of BKvirus Associated Nephropathy Risk by the NEPHROVIR Method
BKVIR Project: Predictive Biological Method of BKvirus Associated Nephropathy Risk by the NEPHROVIR Method
Enrollment Status: Unknown
Publish Date: April 03, 2024
Intervention Type: Biological
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
Health Economic Analysis of Islet Cell Transplantation for Patients With Severe Forms of Brittle Type 1 Diabetes
Health Economic Analysis of Islet Cell Transplantation for Patients With Severe Forms of Brittle Type 1 Diabetes
Enrollment Status: Unknown
Publish Date: June 24, 2022
Intervention Type: Drug, Procedure
Study Drug: Best Medical Care
Study Phase: Phase 3
Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial HYPOREME
Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial HYPOREME
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
Enrollment Status: Terminated
Publish Date: July 13, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).
Enrollment Status: Completed
Publish Date: November 14, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

113 Total Publications

The inhibitory receptor NKG2A is expressed on T-cells during BKPyVANephropathy.
The inhibitory receptor NKG2A is expressed on T-cells during BKPyVANephropathy.
Journal: Frontiers in immunology
Published: October 06, 2025

Frequently Asked Questions about Antoine Durrbach

Is Antoine Durrbach a top-rated expert for Kidney Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Antoine Durrbach is classified as an Elite expert for Kidney Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Antoine Durrbach participate in research or clinical trials?

Yes. Antoine Durrbach has published 113 articles and abstracts on conditions like Kidney Transplant. You can view a list of Antoine Durrbach's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Durrbach's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile